These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 34487739)

  • 1. Thinking inside the box: Current insights into targeting orbital tissue remodeling and inflammation in thyroid eye disease.
    Gupta V; Hammond CL; Roztocil E; Gonzalez MO; Feldon SE; Woeller CF
    Surv Ophthalmol; 2022; 67(3):858-874. PubMed ID: 34487739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teprotumumab for the treatment of thyroid eye disease.
    Fallahi P; Ragusa F; Paparo SR; Elia G; Balestri E; Mazzi V; Patrizio A; Botrini C; Benvenga S; Ferrari SM; Antonelli A
    Expert Opin Biol Ther; 2023 Feb; 23(2):123-131. PubMed ID: 36695097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Efficacy of Teprotumumab in Thyroid Eye Disease: Follow-Up Outcomes in Three Clinical Trials.
    Kahaly GJ; Subramanian PS; Conrad E; Holt RJ; Smith TJ
    Thyroid; 2024 Jul; 34(7):880-889. PubMed ID: 38824618
    [No Abstract]   [Full Text] [Related]  

  • 4. A Paradigm Shift in the Management of Thyroid Eye Disease How Teprotumumab Has Changed the Therapeutic Interface.
    Ugradar S; Kossler AL; Douglas R; Cockerham K
    J Neuroophthalmol; 2022 Mar; 42(1):26-34. PubMed ID: 35500236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of teprotumumab therapy in patients with long-duration thyroid eye disease.
    Subramanian PS; Cho RI; Kahana A
    Curr Opin Ophthalmol; 2023 Nov; 34(6):487-492. PubMed ID: 37610428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the Treatment of Thyroid Eye Disease Associated Extraocular Muscle Myopathy and Optic Neuropathy.
    Lu TJ; Amarikwa L; Sears CM; Kossler AL
    Curr Neurol Neurosci Rep; 2022 Jun; 22(6):313-325. PubMed ID: 35614367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teprotumumab: A Review in Thyroid Eye Disease.
    Nie T; Lamb YN
    Drugs; 2022 Nov; 82(17):1663-1670. PubMed ID: 36418673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease.
    Jain AP; Gellada N; Ugradar S; Kumar A; Kahaly G; Douglas R
    Br J Ophthalmol; 2022 Feb; 106(2):165-171. PubMed ID: 33172865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
    Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
    N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
    Douglas RS; Kahaly GJ; Ugradar S; Elflein H; Ponto KA; Fowler BT; Dailey R; Harris GJ; Schiffman J; Tang R; Wester S; Jain AP; Marcocci C; Marinò M; Antonelli A; Eckstein A; Führer-Sakel D; Salvi M; Sile S; Francis-Sedlak M; Holt RJ; Smith TJ
    Ophthalmology; 2022 Apr; 129(4):438-449. PubMed ID: 34688699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease.
    Men CJ; Amarikwa L; Pham B; Sears C; Clauss K; Lee BW; Lee WW; Pasol J; Ugradar S; Shinder R; Cockerham K; Wester S; Douglas R; Kossler AL
    Ophthalmic Plast Reconstr Surg; 2024 May-Jun 01; 40(3):276-285. PubMed ID: 37972960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
    Winn BJ; Kersten RC
    Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives.
    Mishra S; Maurya VK; Kumar S; Ankita ; Kaur A; Saxena SK
    Curr Eye Res; 2020 Nov; 45(11):1325-1341. PubMed ID: 32567373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on thyroid eye disease: Regional variations in prevalence, diagnosis, and management.
    Yu CY; Ford RL; Wester ST; Shriver EM
    Indian J Ophthalmol; 2022 Jul; 70(7):2335-2345. PubMed ID: 35791115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease.
    Smith TJ
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S13-S26. PubMed ID: 36346686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Objective Diplopia Outcomes for Patients Treated With Teprotumumab for Thyroid Eye Disease.
    Mudalegundi S; Huang P; Henderson AD; Carey AR
    J Neuroophthalmol; 2024 Mar; 44(1):80-86. PubMed ID: 38294416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Experience With Teprotumumab in Patients With Dysthyroid Optic Neuropathy.
    Tamhankar MA; Pradeep T; Chen Y; Briceño CA
    J Neuroophthalmol; 2024 Mar; 44(1):74-79. PubMed ID: 37751310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity.
    Douglas RS; Couch S; Wester ST; Fowler BT; Liu CY; Subramanian PS; Tang R; Nguyen QT; Maamari RN; Ugradar S; Hsu K; Karon M; Stan MN
    J Clin Endocrinol Metab; 2023 Dec; 109(1):25-35. PubMed ID: 37925673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of asymmetric thyroid eye disease with teprotumumab.
    Ugradar S; Wang Y; Mester T; Kahaly GJ; Douglas R
    Br J Ophthalmol; 2022 Jun; 106(6):755-759. PubMed ID: 33579690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.